EyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional Shares
1. EyePoint completed public offering of 14.6 million shares at $11 each. 2. Gross proceeds total approximately $161 million for clinical development efforts. 3. Funds will support DURAVYU development for wet AMD and DME. 4. Phase 3 trial results for DURAVYU expected in 2026. 5. Company addresses ongoing clinical and regulatory uncertainties.